Search clinical trials for: Autologous hematopoietic stem cell transplant (AHSCT)

Total 66693 results

European Society for Blood and Marrow Transplantation

Not yet recruiting

Observational Study in Multiple Sclerosis Patients Treated With Autologous Hematopoietic Stem Cell Transplantation (OMST)

Multiple Sclerosis
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield; Nottingham Trent University; Sheffield Hospitals Charity

Recruiting

Biomarkers of aHSCT (BIO-MS)

Multiple Sclerosis, Relapsing-Remitting

United Kingdom
European Society for Blood and Marrow Transplantation

Recruiting

EBMT ADWP Prospective Non-interventional Study: Post-AHSCT Management in SSC Patients (NISSC-2) (NISSC-2)

Autoimmune Diseases

France
University of Calgary

Terminated

Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (SCT-NMO)

Neuromyelitis Optica

Canada
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
Makati Medical Center

Unknown

Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis

Multiple Sclerosis

Philippines
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

Lymphoma
Lawson Health Research Institute

Unknown

Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients

Malignant Hematologic Neoplasm

Canada
Shanghai Jiao Tong University School of Medicine

Completed

Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes

Type 1 Diabetes Mellitus

China
Regimmune Corporation

Completed

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Graft Versus Host Disease

United States
University of Nebraska

Completed

Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

Lymphoma

United States
Yao Liu

Recruiting

Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma

Lymphoma | Multiple Myeloma

China
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Completed

Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT (Alloforb)

Obstructive Airway Disease

France
Fondazione Italiana Linfomi ONLUS

Completed

Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT (IIL-ProHLRec)

Hodgkin's Lymphoma

Italy
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

AML | MDS

France
Amgen

Terminated

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

High-risk Diffuse Large B-cell Lymphoma

United States, Italy, Belgium, Switzerland, Australia, France, Greece
St. Petersburg State Pavlov Medical University

Recruiting

AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
University of California, Irvine

Recruiting

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)

Allogeneic Hematopoietic Stem Cell Transplantation | Hematologic Malignancies | Allogeneic Stem Cell Transplantation

United States
Emory University
National Cancer Institute (NCI); Gateway for Cancer Research

Recruiting

Personalized Autologous Transplant for Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Terminated

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Breast Cancer | Ovarian Cancer

United States
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN); Blood...

Recruiting

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

Relapsing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

Plasma Cell Myeloma

United States
University of Nebraska

Terminated

Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation

Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center

Completed

Cellular Therapy With Cord Blood Cells

Lymphoma | Leukemia | Multiple Myeloma

United States
Novartis Pharmaceuticals

Recruiting

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Acute Myeloid Leukemia

Spain, Germany, Italy, France
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Terminated

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Lymphoma | Leukemia | Myelodysplastic Syndrome | Hematological Malignancies

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center

Completed

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Fred Hutchinson Cancer Center
ADC Therapeutics

Withdrawn

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent High... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type

United States, Saudi Arabia
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Extraocular Retinoblastoma

United States, Canada, Australia, Brazil, Argentina, Egypt
National Cancer Institute (NCI)

Withdrawn

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

AL Amyloidosis
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Anaplastic Medulloblastoma | Supratentorial Embryonal Tumor, Not Otherwise Specified

United States, Canada, Australia, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Childhood Atypical Teratoid/Rhabdoid Tumor

United States, Canada, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 Neuroblastoma | Stage 1 Neuroblastoma | Stage 2 Neuroblastoma

United States, Canada, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Neuroblastoma | Ganglioneuroblastoma

United States, Canada, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States
Peking University

Recruiting

Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)

Nodal T-follicular Helper Cell Lymphoma

China
Uppsala University
Dalarna County Council, Sweden; Uppsala County Council, Sweden

Not yet recruiting

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Myeloma Multiple
Tianjin Medical University General Hospital

Not yet recruiting

Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis

Multiple Sclerosis
University Hospital Ostrava

Recruiting

The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related to QoL in MS Patients

Multiple Sclerosis | Lower Urinary Tract Symptoms

Czechia
Novartis Pharmaceuticals

Recruiting

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

Sickle Cell Disease

United States
Children's Hospital of Fudan University
CorrectSequence Therapeutics Co., Ltd

Recruiting

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

Beta-Thalassemia

China

Search clinical trials for: Autologous hematopoietic stem cell transplant (AHSCT)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations